Patrys Limited Faces Delay in PAT-DX1 Drug Development
Company Announcements

Patrys Limited Faces Delay in PAT-DX1 Drug Development

Patrys Limited (AU:PAB) has released an update.

Patrys Limited reports a delay in the GMP manufacturing run of its cancer-targeting antibody drug PAT-DX1, due to a process inconsistency in specification testing at their Contract Development Manufacturing Organization. The issue is being addressed, with testing and potential drug release for clinical trials now expected in the second half of August 2024. This setback impacts the timeline for initiating clinical development for PAT-DX1, a promising treatment for various cancers.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Shifts Focus to Promising Antibody PAT-DX3
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Announces Virtual AGM for 2024
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Refocuses on Promising PAT-DX3 Antibody
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App